A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2
NCT03580278
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
BIOLOGICAL:
ABY-035/AFO2
Sponsor
Affibody